dacomitinib

E2190164 UNEXPLORED

Dacomitinib is an oral, irreversible pan-ErbB tyrosine kinase inhibitor used primarily to treat non-small cell lung cancer with specific EGFR mutations.

Try in SPARQL Jump to: Surface forms Referenced by

All labels observed (1)

Label	Occurrences
dacomitinib canonical	1

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

EGFR → targetOfDrug → dacomitinib ⓘ